Anthropic Expands Into Drug Discovery Using AI

AI company Anthropic announced on June 30, 2026, that it will begin developing its own drugs. According to company executives, the move is intended to provide the firm with hands-on experience using its AI products to solve real scientific problems, coinciding with the launch of a new application called Claude Science.

The announcement took place during an event in San Francisco. Anthropic executives stated the company wants to move beyond simply training models and building products for others to use. The firm now intends to apply its internal technology to the drug discovery process.

Eric Kauderer-Abrams, the head of life sciences at Anthropic, said the company questioned what it should be doing in addition to its core model development. This internal inquiry led to the decision to enter the drug development space, as reported by STAT.

Why is Anthropic developing its own drugs?

Anthropic is pursuing drug development to validate its AI tools in a practical, scientific setting. While many AI firms act as software providers for pharmaceutical companies, Anthropic executives emphasized the necessity of getting direct experience with the failures and successes of the laboratory process.

By acting as its own client, the company can identify gaps in its AI’s reasoning or capabilities when faced with biological data. This feedback loop allows the company to refine its models based on actual scientific outcomes rather than theoretical benchmarks.

What is Claude Science?

Claude Science is the newest application released by Anthropic, specifically designed for scientific research. The company launched the tool in San Francisco on June 30, 2026, as the primary engine for its drug development efforts.

While the company has not released full technical specifications for the application, it is positioned as a specialized version of the Claude AI suite tailored for the complexities of biotechnology and pharmaceutical research.

Will Anthropic commercialize these drug candidates?

It remains unclear if Anthropic intends to bring any resulting drug candidates to market. The current focus, according to company leadership, is the application of AI to solve scientific problems rather than the business of pharmaceutical sales.

This approach differs from the traditional “platform-to-pipeline” strategy used by other AI-driven biotech firms. Typically, companies in this sector either license their platform to Big Pharma or build a proprietary pipeline to earn royalties and milestone payments from commercialized drugs.

Anthropic’s current stated goal is the acquisition of experience. Whether the company will eventually seek FDA approval for its own candidates or partner with established pharmaceutical firms for clinical trials has not been disclosed.

How does this fit into current AI drug discovery trends?

The move reflects a broader trend where AI developers are integrating more deeply into the “wet lab” side of science. For years, AI in drug discovery focused primarily on protein folding or small-molecule screening. Now, companies are attempting to automate the iterative cycle of hypothesis, testing, and refinement.

By developing its own drugs, Anthropic is shifting from a tool-provider role to a practitioner role. This transition allows an AI firm to control the entire data chain, from the initial digital prediction to the physical biological result.